Alias Robotics

As an active CVE Numbering Authority since 2020, the company has sustained a steady public output of vulnerability research (30+ CVE IDs issued) and product iteration across CAI, its security LLMs, and the Robot Immune System, a meaningfully faster research cadence than most companies of its size.

Its tools (an agentic CLI, an endpoint-style Robot Immune System) are built for a narrow robotics/OT deployment context that most security teams have no existing tooling for, which is a good fit for that niche but means less turnkey integration into conventional enterprise security stacks.

Disclosed funding is modest -- roughly EUR0.75M in pre-seed from Baron Capital plus EU EIC Accelerator and grant support -- putting total raised in the low single-digit millions; this reflects a research-driven company still building commercial scale rather than one with strong disclosed revenue or growth metrics.

Applying automation and, more recently, purpose-built LLMs to robot and OT security is a genuinely underserved angle -- most security vendors do not treat robot software stacks (ROS, proprietary firmware) as a first-class target -- giving Alias Robotics a distinct technical position rather than a repackaged IT security offering.

Efficacy here is unusually well documented by independent sources: the company's ROS vulnerability research has been cited by CISA and presented at Black Hat 2021, it publicly disclosed vulnerabilities in Mobile Industrial Robots and other manufacturers' products affecting thousands of deployed units, and its CVE Numbering Authority status means its findings go through MITRE's own verification process.

Robot and industrial-automation security is a real and growing concern as manufacturing, logistics, and service robotics scale, but it remains a narrower buyer segment than general enterprise IT or cloud security, which caps near-term market relevance relative to broader categories.